Hormones and breast cancer: Evidence and implications for consideration of risks and benefits of hormone replacement therapy

Journal of Women's Health

Volumn 8, Issue 3, 1999, Pages 347-357

  Colditz, Graham A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE; ORAL CONTRACEPTIVE AGENT;

ADULT; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; ESTROGEN THERAPY; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; MORTALITY; OSTEOPOROSIS; PATIENT COUNSELING; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0032949905     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1999.8.347     Document Type: Review

References (85)

1. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst 1980;65:559.
2. Rosner B, Colditz GA. Extended mathematical model of breast cancer incidence in the Nurses' Health Study. J Natl Cancer Inst 1996;88:359.
3. Burch J, Byrd B. Effects of long-term administration of estrogen. Ann Surg 1971;174:414.
4. Steinberg KK, Thaker SB, Smith SJ, et al. A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985.
5. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: The role of study design in meta-analysis. Epidemiology 1994; 5:415.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Combined reanalysis of data from 51 epidemiological studies involving 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047.
7. Lane-Claypon JE. A further report on cancer of the breast, with special reference to its associated antecedent conditions. London: Ministry of Health, 1926.
8. Rosner B, Colditz G. Extended mathematical model of breast cancer incidence in the Nurses' Health Study. J Natl Cancer Inst 1996;88:359.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiologic studies. Lancet 1996;347:1713.
10. Blohm PL, Hammond CB. Oral estrogen replacement. In: Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven, 1996:1797.
11. Adashi EY. Transdermal estrogen replacement. In: Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive endocrinology, surgery, and technology. Philadelphia: Lippincott-Raven, 1996:1783.
12. Key TJ, Pike MC. The role of estrogens and progestogens in the epidemiology of and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24:29.
13. Hankinson SE, Willett WC, Manson JE, et al. Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 1995;87:1297.
14. Thomas HV, Key TJ, Allen DS, et al. Reversal of relation between body mass index and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1997;89:396.
15. Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer 1989;44:23.
16. Adami HO, Rimsten A, Stenkvist B, Vegelius J. Influence of height, weight, and obesity on risk of breast cancer in an unselected Swedish population. Br J Cancer 1977;36:787.
17. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407.
18. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. Cancer 1995;76:275.
19. Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM, Brown RL. Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 1990; 82:1684.
20. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339:1.
21. Fisher B, Costantino J, Wickerham D, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371.
22. Hankinson SE, Manson JE, London SJ, Willett WC, Speizer FE. Laboratory reproducibility of endogenous hormone levels in postmenopausal women. Cancer Epidemiol Biomarkers Prev 1994;3:51.
23. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190.
24. Cauley J, Lucas F, Kuller L, Stone K, Cummings S, for the Study of Osteoporotic Fractures Research Group. Is bone mineral density a biological marker of a woman's cumulative exposure to estrogen? Rochester, MN: American Epidemiological Society, 1997.
25. Thomas HV, Key TJ, Moore JM, Dowsett M, Fentiman IS, Wang DY. A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. Br J Cancer 1997;76:401.
26. Hankinson S, Willett W, Manson J, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998; 90:1292.
27. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 1994;18:79.
28. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291.
29. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1996;5:533.
30. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 1987;125: 791.
31. Garland CF, Freidlander NJ, Barrett-Connor E, Khaw KT. Sex hormones and postmenopausal breast cancer: A prospective study in an adult community. Am J Epidemiol 1992;135:1220.
32. Thomas HV, Reeves GK, Key TJA. Endogenous estrogen and postmenopausal breast cancer: A quantitative review. Cancer Causes Control 1997;8:922.
33. Zeleniuch-Jacquotte A, Bruning FP, Bonfrer JM, et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol 1997;145: 1030.
34. Grady D, Rubin S, Petitti D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016.
35. Erlik Y, Meldrum D, Judd H. Estrogen levels in post-menopausal women with hot flashes. Obstet Gynecol 1982;59:403.
36. Hagen C, Christiansen M, Tranbol I. Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl, oestradiol-17beta and androstenedione in the early post-menopausal period. Acta Endocrinol 1982;101:87.
37. Mango D, Scirpa P, Battaglia F, Bini E. Plasma androstenedione and oestrone levels in the climacteric syndrome. Maturitas 1984;5:245.
38. Longcope C, Crawford S, McKinlay S. Endogenous estrogens: Relationship between estrone, estradiol, non-protein bound estradiol, and hot flashes and lipids. Menopause 1996;3:77.
39. Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. Am J Epidemiol 1994;140:439.
40. Bauer D, Browner W, Cauley J. Factors associated with appendicular bone mass in older women. Ann Intern Med 1993;118:657.
41. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Platinga P. Prior use of estrogen replacement therapy: Are users healthier than nonusers? Am J Epidemiol 1996;143:971.
42. Langenberg P, Kjerulff KH, Stolley PD. Hormone replacement and menopausal symptoms following hysterectomy. Am J Epidemiol 1997;146:870.
43. Barrett-Connor E. Postmenopausal estrogen and the risk of breast cancer. Ann Epidemiol 1994;4:177.
44. Willis D, Calle E, Miracle-McMahill H, Heath C. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449.
45. Schuurman A, van den Brandt P, Goldbohm R. Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands cohort study. Cancer Causes Control 1995;6:416.
46. Isaacs AJ, Britton AR, McPherson K. Why do women doctors in the UK take hormone replacement therapy? J Epidemiol Community Health 1997;51:373.
47. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927.
48. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605.
49. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589.
50. Pike M, Ross R, Spicer D. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998;147:718.
51. Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargus R. Menopausal hormone replacement therapy and risk of breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286.
52. Colditz G, Egan K, Stampfer M. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168: 1473.
53. Dupont W, Page D. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67.
54. Bergkvist L, Adami H-O, Persson I, Bergstrom R, Krusemo U. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989; 130:221.
55. Strickland D, Gambrell R, Butzin C, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992; 80:400.
56. Brinton LA. Hormones and risk of cancers of the breast and ovary [editorial]. Cancer Causes Control 1996;7:569.
57. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415.
58. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemiol Rev 1993;15:17.
59. Anderson TJ, Battersby S, King RB, et al. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989;20:1139.
60. Williams G, Anderson E, Howell A, et al. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal breast. Int J Cancer 1991;48:206.
61. Clarke C, Sutherland R. Progestin regulation of cellular proliferation: Update 1993. In: Horwitz K, ed. Endocrine review. Monograph 1. Endocrine aspects of cancer. Bethesda, MD: Endocrine Society, 1993:132.
62. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174:93.
63. Myers J, Connor R. Cell proliferation in fibrocystic disease and postmenopausal breast ducts measured by thymidine labeling. Cancer 1982;50:746.
64. Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs SH. Mammographic changes in post-menopausal women on hormonal replacement therapy. Eur Radiol 1997;7:749.
65. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201.
66. Kaufman Z, Garstin WI, Hayes B, Michell MJ, Baum M. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991;43:389.
67. Laya M, Larson E, Taplin S, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643.
68. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203.
69. Colditz GA, Frazier AL. Model of breast cancer shows that risk is set by events of early life: Prevention efforts must shift focus. Cancer Epidemiol Biol Prev 1995;4:567.
70. Tomatis L, Aitio A, Day NE, et al. Cancer: Causes, occurrence and control. Lyon: International Agency for Research on Cancer, 1990. IARC Scientific Publications No. 100, vol 100.
71. Hill AB. The environment and disease: Association or causation? Proc R Soc Med 1965;58:295.
72. Weed DL, Gorelic LS. The practice of causal inference in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 1996;5:303.
73. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. Br Med J 1995;311;1356.
74. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
75. National Center for Health Statistics. Health. United States, 1996-97. Hyattsville, MD: Public Health Service, 1997.
76. Kosary C, Ries L, Miller B, Hankey B, Harras A, Edwards B. SEER cancer statistics review, 1973-1992: Tables and graphs. Bethesda MD: National Cancer Institute, 1995, vol NJH Pub No. 96-2789.
77. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;132:612.
78. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women: Risk within the "normal" weight range. JAMA 1995; 273:461.
79. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81.
80. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willert WC. A prospective study of vitamin E consumption and risk of coronary disease in women. N Engl J Med 1993;328:1444.
81. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359.
82. Giovannucci EL, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998;129: 517.
83. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641.
84. McGovern P, Pankow J, Sharar E, et al. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care, and risk factors. N Engl J Med 1996; 334:884.
85. Grodstein F, Stampfer MJ, Colditz GA, et al. Post-menopausal hormone therapy and mortality. N Engl J Med 1997;336:1769.